公开(公告)号：US20150258175A1

公开(公告)日：2015-09-17

申请号：US14443602

申请日：2013-11-19

Applicant: Agency for Science, Technology and Research

Inventor： Qiang Yu ,  Zhen Ning Wee

IPC: A61K38/21 ,  C12N15/113 ,  C12Q1/68 ,  G01N33/574 ,  A61K31/437 ,  C07K16/40

CPC classification number: A61K38/217 ,  A61K31/437 ,  A61K31/706 ,  A61K31/713 ,  C07K16/40 ,  C07K2317/76 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Y201/01043 ,  G01N33/57492 ,  G01N33/57496 ,  G01N2800/52 ,  A61K2300/00

Abstract: The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.

Abstract translation: 本发明涉及包含组蛋白赖氨酸N-甲基转移酶EZH2（泽斯特同系物2的增强子）抑制剂和干扰素-γ受体活性增强剂的药物组合物。 本发明还涉及治疗患有癌症的患者的方法，包括给药该药物组合物。

公开(公告)号：US09040286B2

公开(公告)日：2015-05-26

申请号：US13147713

申请日：2010-02-03

Applicant: Leonard I. Zon ,  Craig Ceol ,  Yariv J. Houvras

Inventor： Leonard I. Zon ,  Craig Ceol ,  Yariv J. Houvras

IPC: C12M3/00 ,  C12N9/10 ,  G01N33/53 ,  C07K16/40 ,  C12N15/113 ,  G01N33/574

CPC classification number: G01N33/5743 ,  A61K39/39558 ,  C07K16/40 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Y201/01043 ,  G01N33/574 ,  G01N2333/91011 ,  G01N2333/91017

Abstract: Provided herein are methods for diagnosing cancer by determining the level of expression of SETDB1 in a biological sample. Also provided herein are methods for treating cancer by administering an inhibitor of SETDB1 to a subject in need thereof.

Abstract translation: 本文提供了通过确定生物样品中SETDB1的表达水平来诊断癌症的方法。 本文还提供了通过向有需要的受试者施用SETDB1抑制剂来治疗癌症的方法。

公开(公告)号：US20140024099A1

公开(公告)日：2014-01-23

申请号：US13945439

申请日：2013-07-18

Applicant: British Columbia Cancer Agency Branch

Inventor： Ryan D. Morin ,  Marco A. Marra ,  Randy D. Gascoyne ,  Joseph M. Connors

IPC: C12Q1/68 ,  C12N9/10

CPC classification number: C12Q1/6886 ,  C07K16/40 ,  C12N9/1007 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Y201/01043 ,  G01N33/57407 ,  G01N33/6872 ,  G01N2800/52

Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.

Abstract translation: 本公开提供了将受试者鉴定为具有B细胞非霍奇金淋巴瘤（NHL）的方法，例如测试来自受试者的样品用于一种或多种生物标志物中的突变。 还描述了用于分类或监测具有或怀疑具有B细胞非霍奇金淋巴瘤的受试者的方法，包括测试样品中一种或多种生物标志物中的突变。

公开(公告)号：US20130195843A1

公开(公告)日：2013-08-01

申请号：US13839597

申请日：2013-03-15

Applicant: British Columbia Cancer Agency Branch

Inventor： Ryan D. Morin ,  Marco A. Marra ,  Andrew J. Mungall ,  Martin Hirst ,  Maria Mendez-Lago ,  Randy D. Gascoyne ,  Joseph M. Connors

IPC: C12Q1/68 ,  C07K16/40 ,  G01N33/68 ,  C12N9/10

CPC classification number: C12Q1/6886 ,  C07K16/40 ,  C12N9/1007 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Y201/01043 ,  G01N33/57407 ,  G01N33/6872 ,  G01N2800/52

Abstract: The disclosure provides a method of identifying a subject as having B-cell non-Hodgkin lymphoma (NHL) such as testing a sample from a subject for a mutation in one or more biomarkers. Also described are methods for classifying or monitoring a subject having, or suspected of having, B-cell non-Hodgkin lymphoma comprising testing the sample for a mutation in one or more biomarkers.

Abstract translation: 本公开提供了将受试者鉴定为具有B细胞非霍奇金淋巴瘤（NHL）的方法，例如测试来自受试者的样品用于一种或多种生物标志物中的突变。 还描述了用于分类或监测具有或怀疑具有B细胞非霍奇金淋巴瘤的受试者的方法，包括测试样品中一种或多种生物标志物中的突变。

公开(公告)号：US20120020953A1

公开(公告)日：2012-01-26

申请号：US13147713

申请日：2010-02-03

Applicant: Leonard I. Zon ,  Craig Ceol ,  Yariv J. Houvras

Inventor： Leonard I. Zon ,  Craig Ceol ,  Yariv J. Houvras

IPC: C12Q1/48 ,  A61K31/7088 ,  A61P35/00 ,  A61K38/02 ,  A61K39/395 ,  G01N33/574 ,  C40B30/04

CPC classification number: G01N33/5743 ,  A61K39/39558 ,  C07K16/40 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Y201/01043 ,  G01N33/574 ,  G01N2333/91011 ,  G01N2333/91017

Abstract: Provided herein are methods for diagnosing cancer by determining the level of expression of SETDB1 in a biological sample. Also provided herein are methods for treating cancer by administering an inhibitor of SETDB1 to a subject in need thereof.

Abstract translation: 本文提供了通过确定生物样品中SETDB1的表达水平来诊断癌症的方法。 本文还提供了通过向有需要的受试者施用SETDB1抑制剂来治疗癌症的方法。

公开(公告)号：US20090191181A1

公开(公告)日：2009-07-30

申请号：US11912860

申请日：2006-06-23

Applicant: Yusuke Nakamura ,  Yoichi Furukawa ,  Ryuji Hamamoto ,  Shuichi Nakatsuru

Inventor： Yusuke Nakamura ,  Yoichi Furukawa ,  Ryuji Hamamoto ,  Shuichi Nakatsuru

IPC: A61K39/395 ,  C12Q1/68 ,  A61P35/00

CPC classification number: G01N33/5011 ,  C12Q1/48 ,  C12Y201/01043 ,  G01N33/57407 ,  G01N2333/4736 ,  G01N2333/91011 ,  G01N2500/02

Abstract: The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified. N-terminal truncated forms of SMYD3 (alias ZNFN3A1) have higher methylating activity. Lys 824 is a preferred methylation site on the RB1 protein for SMYD3.

Abstract translation: 本发明的特征在于确定多肽的甲基转移酶活性并筛选甲基转移酶活性的调节剂的方法，更特别是用于通过SMYD3进行视网膜母细胞瘤甲基化的调节剂。 本发明还提供了使用所鉴定的调节剂预防或治疗结肠直肠癌，肝细胞癌，膀胱癌和/或乳腺癌的方法或药物组合物。 SMYD3（别名ZNFN3A1）的N-末端截短形式具有较高的甲基化活性。 Lys 824是SMYD3的RB1蛋白上优选的甲基化位点。